Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: One-year follow-up results of the assessment of the safety of a new thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction

American Heart Journal

Volumn 147, Issue 6, 2004, Pages 993-998

  Sinnaeve, Peter R ^a,b   Alexander, John H ^b   Bogaerts, Kris ^a   Belmans, Ann ^a   Wallentin, Lars ^c   Armstrong, Paul ^d   Adgey, Jennifer A A ^e   Tendera, Michal ^f   Diaz, Rafael ^g   Soares Piegas, Leopoldo ^h   Vahanian, Alec ⁱ   Granger, Christopher B ^b   Van De Werf, Frans J ^a,j  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF ALBERTA   (Canada)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g Etudios Cardiologica Latin America Rosario   (Argentina)

^h INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

ⁱ BICHAT HOSPITAL   (France)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; TENECTEPLASE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 3042811613     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.12.028     Document Type: Article

References (16)

1. Lincoff A.M., Topol E.J. Illusion of reperfusion does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 88:1993;1361-1374
2. Steg P.G., Goldberg R.J., Gore J.M., et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 90:2002;358-363
3. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 20:2000;101. 2788-94
4. Antman E.M., Gibson C.M., de Lemos J.A., et al. Combination reperfusion therapy with abciximab and reduced dose reteplase results from TIMI 14: the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J. 21:2000;1944-1953
5. Antman E.M., Cooper H.A., Gibson C.M., et al. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction insights from TIMI 14 and InTIME-II. Eur Heart J. 23:2002;928-933
6. Antman E.M., Louwerenburg H.W., Baars H.F., et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation. 105:2002;1642-1649
7. Ross A.M., Molhoek P., Lundergan C., et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. 104:2001;648-652
8. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13
9. Simoons M., Krzeminska-Pakula M., Alonso A., et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction the AMI-SK study. Eur Heart J. 23:2002;1282
10. de Lemos J.A., Antman E.M., Gibson C.M., et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction observations from the TIMI 14 trial. Circulation. 101:2000;239-243
11. Simes R.J., Topol E.J., Holmes D.R. Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation. 91:1995;1923-1928
12. Gibson C.M., Karha J., Murphy S.A., et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 42:2003;7-16
13. Dubois C.L., Belmans A., Granger C.B., et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol. 42:2003;1178-1185
14. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition the GUSTO V randomised trial. Lancet. 357:2001;1905-1914
15. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 344:2001;1895-1903
16. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Circulation 2003;108:1316-23